Alvogen announced the launch of Rivastigmine Transdermal System, the generic version of NovartisExelon patch.

Exelon is a reversible acetylcholinesterase inhibitor (carbamate derivative) indicated for mild to moderate dementia associated with Parkinson’s disease and for the treatment of dementia of the Alzheimer’s type. It is thought to exert its therapeutic effect by enhancing cholinergic function by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. The effect of rivastigmine may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact.

RELATED: Can Losing Weight Reduce Alzheimer’s Risk?

Rivastigmine Transdermal System is available as 4.6mg/24hrs, 9.5mg/24hrs, and 13.3mg/24hrs strengths.

For more information call (973) 796-3400 or visit